Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric Cancer
Gastric cancer patients taking the immune-boosting drug Opdivo in a clinical trial had a disease control rate of 39%, according to a... Read More
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
MacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
First-Line Pembrolizumab and Trastuzumab in HER2-Positive Esophageal, Gastric, or Gastroesophageal Junction Cancer
Patients with Her2-positive gastric cancer taking a combination of the immune-boosting drug Keytruda with Herceptin had progression-free survival rate at six months... Read More
ctDNA Identifies Acquired Resistance Mechanisms to Savolitinib in MET+ Gastric Cancer
An early trial of AstraZeneca’s MET inhibitor savolitinib in gastric cancer revealed mutations that confer drug resistance.
Enhertu granted Orphan Drug Designation in the US for gastric cancer
AstraZeneca and Daiichi Sankyo won breakthrough designation and orphan drug designation from the FDA for Enhertu in treating HER2-positive gastric cancer, which... Read More
HIPEC With Cisplatin, Mitomycin, and Paclitaxel for Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology
Gastric cancer patients whose disease had spread to the peritoneum received infusions of mitomycin, cisplatin and paclitaxel into the peritoneum in a... Read More
Immunotherapy with Anti-PD-1 Effective for Patients with Solid Tumors
A review of 13 clinical trials published in JAMA Oncology found that patients with solid tumors, including stomach tumors, had better survival... Read More
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
At ASCO GI, Leap Therapeutics announced that in a trial of DKN-01 in patients with advanced gastric cancer, elevated expression of DKK1... Read More
Association of Acupuncture and Acupressure With Improved Cancer Pain
A review of clinical trials reveals that acupuncture and acupressure help reduce pain and opioid usage in cancer patients.
Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint
The new targeted drug Enhertu showed a promising response rate in a trial of patients with HER2-positive gastric cancer.
